Y-mAbs Therapeutics (YMAB) Competitors

Ardelyx (NASDAQ:ARDX) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Which has stronger valuation and earnings, ARDX or YMAB?

Y-mAbs Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$386.15M	4.09	-$39.14M	-$0.23	-28.52
Y-mAbs Therapeutics	$87.68M	4.45	-$29.67M	-$0.50	-17.16

Is ARDX or YMAB more profitable?

Ardelyx has a net margin of -14.60% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-14.60%	-36.57%	-13.42%
Y-mAbs Therapeutics	-26.03%	-24.60%	-18.89%

Which has more risk and volatility, ARDX or YMAB?

Ardelyx has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Does the media refer more to ARDX or YMAB?

In the previous week, Ardelyx had 14 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 17 mentions for Ardelyx and 3 mentions for Y-mAbs Therapeutics. Ardelyx's average media sentiment score of 1.26 beat Y-mAbs Therapeutics' score of 1.26 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	12 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Y-mAbs Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ARDX or YMAB?

Ardelyx currently has a consensus target price of $11.70, indicating a potential upside of 78.35%. Y-mAbs Therapeutics has a consensus target price of $9.62, indicating a potential upside of 12.15%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Y-mAbs Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.10
Y-mAbs Therapeutics	2 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Do insiders & institutionals believe in ARDX or YMAB?

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ardelyx beats Y-mAbs Therapeutics on 11 of the 17 factors compared between the two stocks.